Новини фондового ринку
Останні фінансові новини · Оновлено Лип 24, 2026
Роздрібний гігант закриває останній магазин у ключовому місті після 26 років
Mall retail giant closes final store in key city after 26 years
Despite positive trends like 7% Gap brand growth and 39% digital penetration, the panel is concerned about Athleta's 10% decline …
AMD Щойно досягла рекордного максимуму -- чи запізно купувати?
AMD Just Hit an All-Time High -- Is it Too Late to Buy?
The panel discusses AMD's record-breaking quarter, with concerns around valuation, supply chain constraints, and demand visibility. The key debate revolves …
Acuta Capital зробила ставку на Erasca (ERAS) і цільове лікування раку, купивши 354 575 акцій
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
Despite Acuta Capital's significant investment, the panel is largely bearish due to ERAS-0015 trial's patient death, high cash burn rate, …
Чи Kailera Therapeutics є вигідною інвестицією після її запального IPO?
Is Kailera Therapeutics a Buy After Its Sizzling IPO?
Kailera Therapeutics' IPO is considered high-risk due to intense competition, lack of approved products, and substantial clinical and regulatory risks. …
Чи варто купувати акції LegalZoom після того, як генеральний директор придбав 125 000 акцій?
Is LegalZoom Stock a Buy After the CEO Purchased 125,000 Shares?
Despite a CEO buy signal, the panel is largely bearish due to LegalZoom's eroding moat from AI disruption, anemic margins, …
Грег Абель купує акції, ймовірно, улюбленої акції Воррена Баффета. Чи варто її купувати й вам?
Greg Abel Is Buying Shares of What Is Probably Warren Buffett's Favorite Stock. Should You Buy It Too?
Panelists generally agree that Berkshire Hathaway's current cash hoard and buyback activity signal a defensive posture rather than a growth …
Patient Square робить велику ставку на Nektar Pharmaceuticals (NKTR), купуючи 210 000 акцій
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
Panelists generally agree that Patient Square's investment in NKTR signals confidence in Rezolve-AD's Phase 2b results, but they caution about …
Уоррен Баффет говорив це роками. 1 ETF від Vanguard втілює цю пораду на практиці.
Warren Buffett Has Been Saying This for Years. 1 Vanguard ETF Puts That Advice Into Practice.
The panel agrees that VOO's high tech concentration (33%) poses significant risk, with potential for amplified volatility during corrections. They …
Ipsen: Дані Corabotase демонструють швидку, стійку ефективність при зморшках міжбрівної ділянки
Ipsen : Corabotase Data Demonstrate Rapid, Durable Efficacy In Glabellar Lines
Ipsen's corabotase shows promising Phase II data with rapid onset and strong 24-week durability versus Dysport, but Phase III results …
Чи варто купувати акції WaterBridge після того, як Ranger Investment збільшив свою частку на 345 000 акцій?
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares?
Despite Gemini's 'regulatory moat' argument, the panel consensus is bearish due to WaterBridge's high debt, lack of consistent profitability, and …
Lime подала заявку на IPO -- Купіть ці акції замість цього
Lime Filed for an IPO -- Buy This Stock Instead
The panel consensus is bearish on Lime's IPO, citing the 'going concern' warning, Lime's debt maturity, and the risk of …
NVent Electric Рада Затвердила Програму Викупу Акцій на $500 Млн
NVent Electric Board Approves $500 Mln Share Repurchase Program
The panel is neutral on NVT's $500M, 3-year buyback program. While the program is shareholder-friendly, the delayed start and lack …